Fundz
Real-time · AI · Cross-signal

LIfT BioSciences just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on LIfT BioSciences, plus every contract, funding round, and exec hire that follows, each with verified, ICP-ranked contacts.

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Get the full Deep Dive on LIfT BioSciences — free.

We'll email your report. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

▶
Watch the 2-minute tour · with sound
Don’t take our word for it — ask the live AI about LIfT BioSciences, free
Try the live AI on LIfT BioSciences — no signupNo signup to start
Your turn — ask anything about LIfT BioSciences and hit Ask. Your first answer is free, no signup.
Tap one:

LIfT BioSciences partners with University of Galway for clinical trial in Ireland

Apr 28, 2025•about 1 year ago

Contract Type

partnership

LondonBiotechnologyHealth CareTherapeutics

Description

LIfT BioSciences has announced a strategic partnership with the University of Galway to conduct a planned clinical trial for their Immunomodulatory Alpha Neutrophils (IMANs) in Ireland. The partnership aims to combine expertise in immunotherapy, oncology, patient care, and advanced manufacturing to enhance LIfT’s clinical-stage research capabilities and accelerate the pathway to delivering IMANs to patients.

Company Information

Company

LIfT BioSciences

Location

London, England, United Kingdom

About

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for LIfT BioSciences's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.